A senior board member of the German chemicals and pharmaceuticals group Hoechst has indicated that it could sell a minority stake in its chemical business, reports the Financial Times. The move would be part of a group reorganization program.
Hoechst has already indicated that it intends to separate out its pharmaceuticals business, Hoechst Marion Roussel (Marketletters passim), and is now saying it plans to run its core chemicals division as a separate business in an effort to increase attractiveness to investors.
The group's share price is thought to be relatively low by the financial community in relation to chemical and drug competitors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze